Skip to content
10-Q

Quarterly Report

Aridis Pharmaceuticals, Inc.

0001493152-23-020599

← back to feed
Filed
Jun 8, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · Jun 2, 2023 36.08M sh
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$4M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$10.17M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $1.32M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $4.88M
Stockholders Equity Q1 2023 · Mar 31, 2023 −$27.88M
Stockholders Equity Q1 2023 · Dec 31, 2022 −$24.23M
Stockholders Equity Q1 2023 · Mar 31, 2022 −$20.41M
Stockholders Equity Q1 2023 · Dec 31, 2021 −$13.11M
Current Liabilities Q1 2023 · Mar 31, 2023 $35.43M
Current Liabilities Q1 2023 · Dec 31, 2022 $36.9M
Total Liabilities Q1 2023 · Mar 31, 2023 $37.32M
Total Liabilities Q1 2023 · Dec 31, 2022 $38.93M
Current Assets Q1 2023 · Mar 31, 2023 $6.57M
Current Assets Q1 2023 · Dec 31, 2022 $11.63M
Total Assets Q1 2023 · Mar 31, 2023 $9.43M
Total Assets Q1 2023 · Dec 31, 2022 $14.7M
Eps Basic Q1 2023 · Mar 31, 2023 −$0.22
Eps Basic Q1 2023 · Mar 31, 2022 −$0.44
Sga Expense Q1 2023 · Mar 31, 2023 $1.81M
Sga Expense Q1 2023 · Mar 31, 2022 $2.16M
Rd Expense Q1 2023 · Mar 31, 2023 $5.53M
Rd Expense Q1 2023 · Mar 31, 2022 $6.45M
Net Income Q1 2023 · Mar 31, 2023 −$6.82M
Net Income Q1 2023 · Mar 31, 2022 −$7.77M
Operating Income Q1 2023 · Mar 31, 2023 −$6.26M
Operating Income Q1 2023 · Mar 31, 2022 −$7.42M
Revenue Q1 2023 · Mar 31, 2023 $1.08M
Revenue Q1 2023 · Mar 31, 2022 $1.19M
Capex Q1 2023 · Mar 31, 2022 $21K